Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aim: The goal of this systematic review was to identify moderators of naltrexone efficacy in the treatment of alcohol dependence. Methods: We searched P ubmed, CINHAL, E mbase, P sycINFO and the C ochrane L ibrary from 1990 to A pril 2012 and reference lists of pertinent review articles, which yielded 622 trial, pooled analysis and review articles. Using pre‐established eligibility criteria, two reviewers independently determined whether abstracts contained evidence of demographic or biological characteristics, i.e. moderators, influencing naltrexone response in alcohol dependence. We assessed each publication for risk of bias and evaluated the strength of the body of evidence for each moderator. Results: Twenty‐eight publications (on 20 studies) met criteria for data synthesis. These included 26 publications from 12 randomized, placebo‐controlled trials, three non‐randomized, non‐placebo studies and one randomized, non‐placebo study. In addition, there were two publications from pooled analyses of four randomized, placebo‐controlled trials. Family history of alcohol problems and the A sn40 A sp polymorphism of the μ‐opioid receptor gene showed a positive association with efficacy in four of five and three of five studies, respectively. Other moderators reported to be associated with efficacy included male sex (two of five studies), pre‐treatment drinking (two of two studies) and high craving (two of five studies). However, the overall risk of bias in the published literature is high. Conclusions: The identification of naltrexone‐responsive alcohol‐dependent patients is still in development. Studies to date point to two potential moderators—family history and presence of the OPRM 1 A sn40 A sp polymorphism—as having the strongest evidence. However, the data to date is still insufficient to recommend that any moderator be used in determining clinical treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Actual Causes of Death in the United States, 2000
Mokdad, A. H. (2004) · JAMA · doi:10.1001/jama.291.10.1238 · Cited by 5,211
Hasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.830 · Cited by 2,908 · cited 1×
“However, only a minority of patients with alcohol dependence receive psychosocial, pharmacological or both treatments—in the order of fewer than 25% [1].”
BackgroundMediators and Moderators of Treatment Effects in Randomized Clinical Trials
Kraemer, H. C., Wilson, G. T., Fairburn, C. G., & Agras, W. S. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.877 · Cited by 2,562
Economic costs of excessive alcohol consumption in the U.S., 2006
Bouchery, E. E., Harwood, H. J., Sacks, J. J., Simon, C. J., & Brewer, R. D. (2011) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.06.045 · Cited by 1,041 · cited 1×
“Alcohol dependence and excessive alcohol use are costly, both in economic terms [2] and in lives lost [3].”
BackgroundOslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571 · cited 2×
“[27] reported that those with the Asn40Asp allele who received naltrexone had lower relapse rates than those without the allele (no effect was found in the placebo group).”
BackgroundOwens, D. K., Lohr, K. N., Atkins, D., Treadwell, J. R., Reston, J. T., Bass, E. B., Chang, S., & Helfand, M. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.03.009 · Cited by 513 · cited 1×
“Recommendations Assessment, Development and Evaluation) approach [14].”
Anton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451 · cited 2×
“Four of the six publications investigating the OPRM1 Asn40Asp polymorphism reported a significant positive association for naltrexone response, although two of these publications [24,25] evaluated the same population.”
BackgroundHow effective is alcoholism treatment in the United States?
Miller, W. R., Walters, S. T., & Bennett, M. E. (2001) · Journal of Studies on Alcohol · doi:10.15288/jsa.2001.62.211 · Cited by 434 · cited 1×
“This is unfortunate, as the treatment of alcohol dependence can be very effective [4].”
BackgroundUnderstanding US addiction physicians' low rate of naltrexone prescription
Mark, T. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00134-0 · Cited by 120
Cited by
Advances in the science and treatment of alcohol use disorder
Witkiewitz, K., Litten, R. Z., & Leggio, L. (2019) · Science Advances · doi:10.1126/sciadv.aax4043 · Cited by 592
Muscogiuri, G., Verde, L., Vetrani, C., Barrea, L., Savastano, S., & Colao, A. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02196-z · Cited by 164
“Interestingly, gender-related differences have been reported in humans in the acute response of the hypothalamic–pituitary–adrenal axis to naltrexone and in the clinical response to this drug in alcohol dependence [53].”
BackgroundFocusing on the Opioid System for Addiction Biomarker Discovery
Belzeaux, R., Lalanne, L., Kieffer, B. L., & Lutz, P.-E. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.12.004 · Cited by 28
What the alcohol doctor ordered from the neuroscientist
Heilig, M., & Leggio, L. (2016) · Progress in Brain Research · doi:10.1016/bs.pbr.2015.07.023 · Cited by 25
Metadata
- Authors
- Garbutt, J. C., Greenblatt, A. M., West, S. L., Morgan, L. C., Kampov‐Polevoy, A., Jordan, H. S., & Bobashev, G. V.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2014-05-23
- Volume
- 109
- Issue
- 8
- Pages
- 1274-1284
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W1871434514
- Cited by
- 81
- References
- 9
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.